Nexalin Technology has regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split, confirmed by Nasdaq and the Nasdaq Hearings Panel. The company must still meet a minimum stockholders' equity requirement by January 4, 2027, to maintain its listing. Nexalin is focusing on commercial revenue growth, including a new distribution agreement in South America, and advancing U.S. clinical trials for its neurostimulation technology. The company aims for FDA marketing authorization and continued Nasdaq listing, but risks remain regarding financial compliance and regulatory approvals.
Nexalin Technology's Nasdaq listing status is the subject, with Pluang's health sector data providing market context. For readers following health stocks, here is Pluang's market snapshot as of Oct 08, 2026 18:43 WIB: out of 128 priced health-sector US stocks, 29 rose and 91 fell. Twist Bioscience Corp (TWST) traded at USD 148.76 with a 1-day change of -4.43% and a typical hold time of 27 days, while Ginkgo Bioworks Holdings Inc (DNA) was at USD 11.07, down 3.49%, with a 7-day hold time. Mesoblast Limited (MESO) stood at USD 13.48, down 3.30%, with a 14-day hold time.
MIND, an AI-native data loss prevention (DLP) platform, was named "Data Loss Prevention Platform of the Year" in the 2026 CyberSecurity Breakthrough Awards. The platform uses advanced AI to discover, detect, and prevent sensitive data leaks across va...
The global Mivan construction market is projected to grow from $3.92 billion in 2025 to $7.05 billion by 2031, at a CAGR of 10.28%. Growth is fueled by demand for rapid mass housing, affordable residential projects, and faster construction enabled by...
RBC Capital has increased its price target for Amgen from $400 to $430, reflecting strong confidence in the biopharmaceutical company's future performance. Amgen's stock has outperformed both the S&P 500 and the broader medical sector recently, suppo...
Tilray Brands reported a wider-than-expected loss of $0.32 per share for Q1 fiscal 2027, missing revenue estimates with $257.1 million, though revenue grew 23% year-over-year. The company achieved record first-quarter gross profit with a 30% gross ma...
UnitedHealth Group is expected to report Q3 earnings of $4.12 per share on $111.3 billion revenue, with investors closely watching medical cost trends and Medicare Advantage membership. The company improved its medical care ratio and operating earnin...
